Cancer Letters
Volume 224, Issue 1 , Pages 31-43 , 16 June 2005

Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro

Received 17 May 2004 ,Revised 30 October 2004 ,Accepted 2 November 2004.

References 

  1. Smets A. Programmed cell death (apoptosis) and response to anti-cancer drugs. Anticancer Drugs. 1994;5:3–9
  2. Giardiello FM, Spannhake EW, DuBois RN, Hylind LM, Robinson CR, Hubbard WC, et al. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig. Dis. Sci. 1998;43:311–316
  3. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000;342:1946–1952
  4. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2001;2:544–551
  5. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493–501
  6. Liu XH, Kirschenbaum A, Yao S, Stearns ME, Holland JF, Claffey K, et al. Upregulation of vascular endothelial growth factor by cobalt chloride simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin. Exp. Metastasis. 1999;17:687–694
  7. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998;58:362–366
  8. Oshima M, Murai N, Kargman S, Arguello M, Luk P, Kwong E, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 2001;61:1733–1740
  9. Piazza GA, Rahm AL, Krutzsch M, Sperl G, Paranka NS, Gross PH, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 1995;55:3110–3116
  10. Shiff SJ, Koutsos MI, Qiao L, Rigas B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp. Cell Res. 1996;222:179–188
  11. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 1997;99:2254–2259
  12. Hara A, Yoshimi N, Niwa M, Ino N, Mori H. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines, Jpn. J. Cancer Res. 1997;88:600–604
  13. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 2000;60:293–297
  14. Ratnakar P, Kiranmai G, Reddanna P, Sutton LN, Phillips PC, Damodar Reddy C. Overexpression of cyclooxygenase-2 in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib. Cancer Lett. 2002;180:13–21
  15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 1983;65:55–63
  16. Hermann M, Lorenz HM, Voll R, Grunke M, Woith W, Kalden JR. A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res. 1994;22:5506–5507
  17. Reddy CM, Bhat VB, Kiranmai G, Reddy MN, Reddanna P, Madyastha KM. Selective inhibition of cyclooxygenase-2 by C-phycocyanin, a biliprotein from Spirulina platensis. Biochem. Biophys. Res. Commun. 2000;277:599–603
  18. Sambrook J, Frotsch CF, Maniatis T. Molecular Cloning. Cold Spring Harbour: Plain view; 1989;
  19. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal. Biochem. 1976;72:248–254
  20. Chaturvedi MM, Kumar A, Darnay BG, Chainy GB, Agarwal S, Aggarwal BB. Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-kappaB activation IkappaBalpha phosphorylation, and degradation. J. Biol. Chem. 1997;272:129–134
  21. Fournier DB, Gordon GB. COX-2 and colon cancer: potential targets for chemoprevention. J. Cell. Biochem. 2000;77:97–102
  22. Fosslein E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit. Rev. Clin. Lab. Sci. 2000;37:431–502
  23. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996;86:147–157
  24. Martinou JC, Desagher S, Antonsson B. Cytochrome c release from mitochondria: all or nothing. Nat. Cell Biol. 2000;2:E41–E43
  25. Shah GM, Shah RG, Poirier GG. Different cleavage pattern of poly (ADP-Ribose) polymerase during necrosis and apoptosis in HL60 cells. Biochem. Biophys. Res. Commun. 1996;229:838–844
  26. Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCap cells. Cancer Res. 1998;58:4245–4249
  27. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998;58:362–366
  28. Goldberg Y, Nassif II, Pittas A, Tsai LL, Dynlacht BD, Rigas B, et al. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene. 1996;12:893–901
  29. Loo DT, Rillema JR. Measurement of cell death. Methods Cell Biol. 1998;57:251–264
  30. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275:1132–1136
  31. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91:479–489
  32. Li M, Wu X, Xu XC. Induction of apoptosis by cyclooxygenase-2 inhibitor NS398 through a cytchrome c- dependent pathway in esophageal cancer cells. Int. J. Cancer. 2001;93:218–223
  33. Madhava C, Subhashini J, Mahipal SVK, Bhat VB, Srinivas Reddy P, Kiranmai G, et al. C-Phycocyanin, a selective cyclooxygenase-2 inhibitor, induces apoptosis in lipopolysaccharide-stimulated RAW 264.7 macrophages. Biochem. Biophys. Res. Commun. 2003;304:385–392
  34. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature. 1994;371:346–347
  35. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat. Med. 1997;3:614–620
  36. Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin. Hematol. 1997;34:9–19
  37. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609–619
  38. Zhang G, Tu C, Zhang G, Zhou G, Zheng W. Indomethacin induces apoptosis and inhibits proliferation in chronic myeloid leukemia cells. Leuk. Res. 2000;24:385–392
  39. J. Subhashini, S.V.K. Mahipal, M.C. Reddy, M. Mallikarjuna Reddy, A. Rachamallu, P. Reddanna, Molecular mechanisms in C-Phycocyanin induced apoptosis in human chronic myeloid leukemia cell line-K562, Biochem. Pharmacol. 68 (2004) 453–462.
  40. Wang CY, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 1996;274:784–787
  41. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 1996;274:787–789
  42. Wang CY, Guttridge DC, Mayo MW, Baldwin AS. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell Biol. 1999;19:5923–5929
  43. Wang CY, Cusack JC, Liu R, Baldwin AS. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med. 1999;5:412–417
  44. Waddick KG, Uckun FM. Innovative treatment programs against cancer: II. Nuclear factor-kappaB (NF-kappaB) as a molecular target. Biochem. Pharmacol. 1999;57:9–17
  45. Kopp E, Ghosh S. Inhibition of NF-kappaB by sodium salicylate and aspirin. Science. 1994;265:956–959
  46. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. Sulindac inhibits activation of the NF-kappaB pathway. J Biol. Chem. 1999;274:27307–27314
  47. Berman KS, Verma UN, Harburg G, Minna JD, Cobb MH, Gaynor RB. Sulindac enhances tumor necrosis factor-alpha-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-kappaB. Clin. Cancer Res. 2002;8:354–360
  48. Woynarowska BA, Woynarowski JM. Preferential targeting of apoptosis in tumor versus normal cells. Biochim. Biophys. Acta. 2002;1587:309–317

PII: S0304-3835(04)00858-4

doi: 10.1016/j.canlet.2004.11.002

Cancer Letters
Volume 224, Issue 1 , Pages 31-43 , 16 June 2005

Article Tools

* Image Usage & Resolution